Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age19+
SponsorDong-A University Hospital
About this trial
This study aims to study the efficacy and safety of oral cyclophosphamide in addition to carfilzomib and dexamethadone for RRMM patients who have been previously exposed to lenalidomide combination therapies.
Eligibility criteria
Qualifiers
Subjects aged 19 years or older
ECOG performance status 0 to 2
Diagnosed with multiple myeloma by IMWG criteria
Subjects previously treated with 1 or more lines of therapy
Disqualifiers
Myocardial infarction within 6 months prior to treatment, New York Heart Association class III or IV heart failure, uncontrolled angina, history of severe coronary artery disease,
Uncontrolled arrythmias (CVDAE version4 grade 2 or more) or symptomatic EKG abnormalities
12-lead EKG : baseline ATcF > 470msec
2D Echocardiography or MUGA scan : systolic EF < 40% with clinically significant symptoms
Trial design
Treatments tested in this trial
- Carfilzomib
- Cyclophosphamide
- Dexamethasone
Treatment groups
49 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Source ClinicalTrials.gov